Cytotoxic T Lymphocyte-Associated Antigen-4 (CTLA-4), also known as CD152, is a transmembrane protein on the surface of T cells encoded by the CTLA-4 gene.

This article summarized the latest R&D progress of Vismodegib, the Mechanism of Action for Vismodegib, and the drug target R&D trends for Vismodegib.

Vividion Therapeutics, Inc., confirmed the commencement of patient dosing for a Phase I cancer clinical trial concerning its experimental oral agent, KEAP1 activator VVD-130037.

This article summarized the latest R&D progress of Vildagliptin, the Mechanism of Action for Vildagliptin, and the drug target R&D trends for Vildagliptin.

Recombinant Cytochrome P450 1A2 (CYP1A2) belongs to the CYP1A subfamily of the CYP1 family and is encoded by the CYP1A2 gene.

This article summarized the latest R&D progress of Sotagliflozin, the Mechanism of Action for Sotagliflozin, and the drug target R&D trends for Sotagliflozin.

NeuroBo Pharmaceuticals, Inc. has started its Phase 2a clinical trial using DA-1241, a unique GPR119 agonist, to treat the first patient with nonalcoholic steatohepatitis.

This article summarized the latest R&D progress of Selumetinib, the Mechanism of Action for Selumetinib, and the drug target R&D trends for Selumetinib.

Growth factors represent a class of polypeptides that regulate cell growth and various other cellular functions through binding with specific, high-affinity cell membrane receptors.

This article summarized the latest R&D progress of Peramivir, the Mechanism of Action for Peramivir, and the drug target R&D trends for Peramivir.

GSK plc has confirmed that Ojjaara(momelotinib), a daily oral JAK1/JAK2 and activin A receptor type 1 inhibitor, has received approval from the US FDA.

This article summarized the latest R&D progress of Pantethine, the Mechanism of Action for Pantethine, and the drug target R&D trends for Pantethine.